Table 4:
Renal medullary and collecting duct histology.
| Agent (trial, year) | Phase | N per group | Primary endpoint | ORR, % (95% CI) | mPFS, months (95% CI) | OS, months (95% CI) |
|---|---|---|---|---|---|---|
| Gemcitabine + cisplatin or carboplatin (2007)(75) | II | 23 Collecting ducts | ORR | 26 (8–44) | 7.1 (3–11.3) | 10.5 (3.8–71.1) |
| Cabozantinib (BONSAI, 2022)(78) |
II | 23 Collecting ducts | ORR | 35 (16–57) | 4 (3–13) | 7 (3–31) |
ORR: overall response rate, mPFS: median progression-free survival, OS: overall survival.